"Gastrointestinal and Liver Stem Cell Research Group" (GILSteR), Department of Internal Medicine, Gemelli Hospital, Catholic University of Rome, Largo A. Gemelli 8-00168 Roma, Italy.
Stem Cells Int. 2010 Sep 1;2010:259461. doi: 10.4061/2010/259461.
Millions of patients worldwide suffer from end-stage liver pathologies, whose only curative therapy is liver transplantation (OLT). Given the donor organ shortage, alternatives to OLT have been evaluated, including cell therapies. Hepatocyte transplantation has been attempted to cure metabolic liver disorders and end-stage liver diseases. The evaluation of its efficacy is complicated by the shortage of human hepatocytes and their difficult expansion and cryopreservation. Recent advances in cell biology have led to the concept of "regenerative medicine", based on the therapeutic potential of stem cells (SCs). Different types of SCs are theoretically eligible for liver cell replacement. These include embryonic and fetal SCs, induced pluripotent cells, annex SCs, endogenous liver SCs, and extrahepatic adult SCs. Aim of this paper is to critically analyze the possible sources of SCs suitable for liver repopulation and the results of the clinical trials that have been published until now.
全球数以百万计的患者患有终末期肝疾病，其唯一的治愈疗法是肝移植（OLT）。鉴于供体器官短缺，已经评估了OLT 的替代方法，包括细胞疗法。已经尝试进行肝细胞移植以治疗代谢性肝疾病和终末期肝病。由于人肝细胞的短缺及其难以扩增和冷冻保存，评估其疗效变得复杂。细胞生物学的最新进展导致了“再生医学”的概念，该概念基于干细胞（SCs）的治疗潜力。不同类型的 SC 理论上适合肝细胞替代。这些包括胚胎和胎儿 SC、诱导多能细胞、附件 SC、内源性肝 SC 和肝外成人 SC。本文的目的是批判性地分析适合肝脏再植的 SC 的可能来源，以及迄今为止已发表的临床试验结果。
